DOCSLIB.ORG

Sexually Transmitted Diseases Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sexually Transmitted Diseases Dr FAST FACTS FOR BOARD REVIEW Series Editor: William W. Huang,MD,MPH W. Series Editor:William Rita Pichardo-Geisinger, MD Rita Pichardo-Geisinger, Diseases Sexually Transmitted Disease Laboratory (Synonym[s]) Etiology Clinical Features Diagnosis Treatment Other Features Chancroid Haemophilus Incubation period: 3–7 d; erythematous Small Oral azithromycin 1 g SD; Prevalent in (soft chancre, ducreyi papule, pustule, and then painful ulcer gram-negative IM ceftriaxone 250 mg SD; promiscuous ulcus molle) on the internal and/or external surface bacilli (school oral ciprofloxacin 500 mg high-risk groups; of the prepuce, coronal sulcus, or of fish pattern); twice daily for 3 d; oral enhances HIV around the frenulum in men; introital isolation in culture erythromycin base transmission; and/or perianal area or on the cervix or (not available 500 mg 4 times daily for 7 d coinfection with vaginal wall in women; painful inguinal commercially) syphilis or herpes lymphadenitis, usually unilateral simplex virus is possible Congenital Treponema Marasmic syphilis, snuffles, perioral/ 19S antibodies on Aqueous crystalline penicillin G syphilis pallidum perianal fissures, lymphadenitis; late chromatography, 100,000–150,000 U/kg congenital syphilis: Hutchinson teeth, FTA-ABS 19S daily administered as interstitial keratitis IgM test, and 50,000 U/kg IV dose every IgM ELISA 12 h during the first 7 d of life and every 8 h thereafter for a total of 10 d; procaine penicillin G 50,000 U/kg IM in a single daily dose for 10 d Gonorrhea Neisseria Incubation period: 1–14 d; dysuria, Gram or Dual treatment with IM Preventive gonorrhoeae urethral purulent discharge; vaginal methylene blue ceftriaxone 250 mg SD and strategies for noconflictofinterest. The authorreports Winston-Salem, NorthCarolina. BaptistMedicalCenter, Forest Wake ofDermatology, isAssociateProfessor Pichardo-Geisinger Dr. discharge, intermenstrual bleeding, staining oral azithromycin 1 g SD ophthalmia menorrhagia, and inflammation of the (gram-negative (recommended by CDC neonatorum Bartholin glands in women; primary diplococci in as first-line treatment); include topical site in women is the endocervical PMNs); culture: IM ceftriaxone 250 mg SD; silver nitrate canal; 10% of men and 50% of women antibiotic- ophthalmia neonatorum: and other are asymptomatic; complications in containing IV ceftriaxone antimicrobial eye men include gonococcal pyoderma, selective media 25–50 mg/kg SD drops; facilitates epididymitis, prostatitis, and seminal (Thayer-Martin HIV transmission vesiculitis; urethral colonization occurs medium); in 70%–90% of women infected with nonamplified gonorrhea; acute salpingitis and pelvic DNA probe test inflammatory disease occur in (hybridization 10%–20% of women; extragenital of gonococcal gonorrhea: oropharyngeal gonorrhea, RNA); nucleic rectal gonorrhea (anal intercourse), acid amplification gonorrheal ophthalmia (blindness); assays for disseminated gonococcal infection: chlamydial and arthritis-dermatitis syndrome, gonococcal gonococcal endocarditis, meningitis; infections ophthalmia neonatorum: inoculation during vaginal delivery, purulent conjunctivitis (continued) Copyright Cutis 2016. This page may be reproduced by dermatologists for noncommercial use. Disease Laboratory (Synonym[s]) Etiology Clinical Features Diagnosis Treatment Other Features Chancroid Haemophilus Incubation period: 3–7 d; erythematous Small Oral azithromycin 1 g SD; Prevalent in (soft chancre, ducreyi papule, pustule, and then painful ulcer gram-negative IM ceftriaxone 250 mg SD; promiscuous ulcus molle) on the internal and/or external surface bacilli (school oral ciprofloxacin 500 mg high-risk groups; of the prepuce, coronal sulcus, or of fish pattern); twice daily for 3 d; oral enhances HIV around the frenulum in men; introital isolation in culture erythromycin base transmission; and/or perianal area or on the cervix or (not available 500 mg 4 times daily for 7 d coinfection with vaginal wall in women; painful inguinal commercially) syphilis or herpes lymphadenitis, usually unilateral simplex virus is possible Congenital Treponema Marasmic syphilis, snuffles, perioral/ 19S antibodies on Aqueous crystalline penicillin G syphilis pallidum perianal fissures, lymphadenitis; late chromatography, 100,000–150,000 U/kg congenital syphilis: Hutchinson teeth, FTA-ABS 19S daily administered as interstitial keratitis IgM test, and 50,000 U/kg IV dose every IgM ELISA 12 h during the first 7 d of life and every 8 h thereafter for a total of 10 d; procaine penicillin G 50,000 U/kg IM in a single daily dose for 10 d Gonorrhea Neisseria Incubation period: 1–14 d; dysuria, Gram or Dual treatment with IM Preventive gonorrhoeae urethral purulent discharge; vaginal methylene blue ceftriaxone 250 mg SD and strategies for discharge, intermenstrual bleeding, staining oral azithromycin 1 g SD ophthalmia menorrhagia, and inflammation of the (gram-negative (recommended by CDC neonatorum Bartholin glands in women; primary diplococci in as first-line treatment); include topical site in women is the endocervical PMNs); culture: IM ceftriaxone 250 mg SD; silver nitrate canal; 10% of men and 50% of women antibiotic- ophthalmia neonatorum: and other are asymptomatic; complications in containing IV ceftriaxone antimicrobial eye men include gonococcal pyoderma, selective media 25–50 mg/kg SD drops; facilitates epididymitis, prostatitis, and seminal (Thayer-Martin HIV transmission vesiculitis; urethral colonization occurs medium); in 70%–90% of women infected with nonamplified ® gonorrhea; acute salpingitis and pelvicCutis DNA probeFast test Facts for Board Review inflammatory disease occur in (hybridization 10%–20% of women; extragenital of gonococcal gonorrhea: oropharyngeal gonorrhea, RNA); nucleic rectal gonorrhea (anal intercourse), acid amplification gonorrheal ophthalmia (blindness); assays for disseminated gonococcal infection: chlamydial and arthritis-dermatitis syndrome, gonococcal gonococcal endocarditis, meningitis; infections ophthalmia neonatorum: inoculation during vaginal delivery, purulent conjunctivitis Disease Laboratory (Synonym[s]) Etiology Clinical Features Diagnosis Treatment Other Features Granuloma Calymmatobacterium Incubation period: 1–4 wk after Donovan bodies Oral azithromycin Differential inguinale granulomatis exposure but symptoms may be on Giemsa, 1 g once weekly or diagnosis includes (donovanosis, delayed for 3–6 mo; painless or mildly Wright, or 500 mg daily for at least 3 carcinoma, granuloma painful papules or nodules that may Leishman staining wk or until all lesions have amebiasis, venereum) bleed; extragenital lesions may be of tissue smears completely healed; alternative tuberculosis, present due to autoinoculation or from active treatments: oral TMP-SMX Crohn disease, dissemination on the skin, bones, lesions; there are 160/800 mg twice daily and pyoderma intra-abdominal, and/or oral cavities no serologic tests for 3 wk; oral doxycycline gangrenosum for diagnosis 100 mg twice daily for 3 wk; oral ciprofloxacin 750 mg twice daily for 3 wk; oral erythromycin base 500 mg 4 times daily for 3 wk Lymphogranuloma Chlamydia Incubation period: 3–30 d; primary Serologic Oral doxycycline 100 mg Differential venereum trachomatis stage: herpetiform lesion on the detection of 2 times daily for 3 wk; diagnosis includes (lymphogranuloma coronal sulcus in men or posterior antibodies against pregnant women: oral chancroid, inguinale, vaginal wall in women with serovars L1-L3 erythromycin base 500 mg lymphoma, Durand-Nicolas- lymphangitis, groove signa; secondary of C trachomatis, 4 times daily for 3 wk and catscratch Favre disease) stage: begins after 2–6 wk, inguinal detection DNA disease; facilitates syndrome, unilateral lymphadenopathy sequence specific HIV transmission with painful erythematous bubo to chlamydia that drains pus and has sinus serovars by PCR tracts; anogenital rectal syndrome: proctocolitis, hyperplasia of the intestinal and perirectal lymphatic tissue, incontinence (continued) Copyright Cutis 2016. This page may be reproduced by dermatologists for noncommercial use. Cutis® Fast Facts for Board Review (continued) Disease (Synonym[s]) Etiology Clinical Features Laboratory Diagnosis Treatment Other Features Syphilis (lues) T pallidum Early syphilis: incubation period, Primary stage: presence of Primary, Syphilis facilitates 21 d; primary stage: painless papule treponemes on dark field secondary, and HIV transmission; that ulcerates as a single indolent, round microscopy; anticardiolipin early latent stage: follow-up or oval, indurated ulcer; secondary antibodies can lead to IM penicillin G examinations are stage: hematogenous and lymphatic false-positive RPR test 2.4 million U SD; recommended dissemination; prodromal symptoms: and false-positive VDRL late latent and at 6 and low-grade fever, malaise, sore throat, test; antibodies to surface tertiary stage: 12 mo following adenopathy, weight loss, muscle aches, proteins to T pallidum in IM penicillin G treatment of headache; nonpruritic papulosquamous TPHA, MHA-TP, or 2.4 million U once early syphilis; late eruption, pink to violaceous to red- FTA-ABS; secondary weekly for 3 wk; syphilis should brown lesions; painless mucosal ulcers stage: presence of neurosyphilis: be evaluated to large gray plaques in genital areas; treponemes on dark IV crystalline once every condyloma lata in the anogenital region, field microscopy, penicillin G 3 years; for CSF lymph node enlargement, nonscarring spirochetes detected 24 million U/d abnormalities,
Load more

Recommended publications
  • Official Nh Dhhs Health Alert
    THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network [email protected] May 18, 2018, 1300 EDT (1:00 PM EDT) NH-HAN 20180518 Tickborne Diseases in New Hampshire Key Points and Recommendations: 1. Blacklegged ticks transmit at least five different infections in New Hampshire (NH): Lyme disease, Anaplasma, Babesia, Powassan virus, and Borrelia miyamotoi. 2. NH has one of the highest rates of Lyme disease in the nation, and 50-60% of blacklegged ticks sampled from across NH have been found to be infected with Borrelia burgdorferi, the bacterium that causes Lyme disease. 3. NH has experienced a significant increase in human cases of anaplasmosis, with cases more than doubling from 2016 to 2017. The reason for the increase is unknown at this time. 4. The number of new cases of babesiosis also increased in 2017; because Babesia can be transmitted through blood transfusions in addition to tick bites, providers should ask patients with suspected babesiosis whether they have donated blood or received a blood transfusion. 5. Powassan is a newer tickborne disease which has been identified in three NH residents during past seasons in 2013, 2016 and 2017. While uncommon, Powassan can cause a debilitating neurological illness, so providers should maintain an index of suspicion for patients presenting with an unexplained meningoencephalitis. 6. Borrelia miyamotoi infection usually presents with a nonspecific febrile illness similar to other tickborne diseases like anaplasmosis, and has recently been identified in one NH resident. Tests for Lyme disease do not reliably detect Borrelia miyamotoi, so providers should consider specific testing for Borrelia miyamotoi (see Attachment 1) and other pathogens if testing for Lyme disease is negative but a tickborne disease is still suspected.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • HIV (Human Immunodeficiency Virus)
    TABLE OF CONTENTS AFRICAN TICK BITE FEVER .........................................................................................3 AMEBIASIS .....................................................................................................................4 ANTHRAX .......................................................................................................................5 ASEPTIC MENINGITIS ...................................................................................................6 BACTERIAL MENINGITIS, OTHER ................................................................................7 BOTULISM, FOODBORNE .............................................................................................8 BOTULISM, INFANT .......................................................................................................9 BOTULISM, WOUND .................................................................................................... 10 BOTULISM, OTHER ...................................................................................................... 11 BRUCELLOSIS ............................................................................................................. 12 CAMPYLOBACTERIOSIS ............................................................................................. 13 CHANCROID ................................................................................................................. 14 CHLAMYDIA TRACHOMATIS INFECTION .................................................................
    [Show full text]
  • Early History of Infectious Disease 
    © Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION CHAPTER ONE EARLY HISTORY OF INFECTIOUS 1 DISEASE Kenrad E. Nelson, Carolyn F. Williams Epidemics of infectious diseases have been documented throughout history. In ancient Greece and Egypt accounts describe epidemics of smallpox, leprosy, tuberculosis, meningococcal infections, and diphtheria.1 The morbidity and mortality of infectious diseases profoundly shaped politics, commerce, and culture. In epidemics, none were spared. Smallpox likely disfigured and killed Ramses V in 1157 BCE, although his mummy has a significant head wound as well.2 At times political upheavals exasperated the spread of disease. The Spartan wars caused massive dislocation of Greeks into Athens triggering the Athens epidemic of 430–427 BCE that killed up to one half of the population of ancient Athens.3 Thucydides’ vivid descriptions of this epidemic make clear its political and cultural impact, as well as the clinical details of the epidemic.4 Several modern epidemiologists have hypothesized on the causative agent. Langmuir et al.,5 favor a combined influenza and toxin-producing staphylococcus epidemic, while Morrens and Chu suggest Rift Valley Fever.6 A third researcher, Holladay believes the agent no longer exists.7 From the earliest times, man has sought to understand the natural forces and risk factors affecting the patterns of illness and death in society. These theories have evolved as our understanding of the natural world has advanced, sometimes slowly, sometimes, when there are profound break- throughs, with incredible speed. Remarkably, advances in knowledge and changes in theory have not always proceeded in synchrony. Although wrong theories or knowledge have hindered advances in understanding, there are also examples of great creativity when scientists have successfully pursued their theories beyond the knowledge of the time.
    [Show full text]
  • Sclerosing Lymphangitis of the Penis
    Brit. J. vener. Dis. (1972) 48, 545 Br J Vener Dis: first published as 10.1136/sti.48.6.545 on 1 December 1972. Downloaded from Sclerosing lymphangitis of the penis A. LASSUS, K. M. NIEMI, S.-L. VALLE, AND U. KIISTALA From the Department of Dermatology and Venereology, University Central Hospital, Helsinki, Finland Non-venereal sclerosing lymphangitis of the penis of the lesion was perforated a clear yellowish fluid leaked (NSLP) has been considered a rare condition, and out and the lesion became softer and smaller. A biopsy only fourteen cases have been reported (Hoffmann, was taken from the wall of the lesion. After the operation, 1923, 1938; von Berde 1937; Nickel and Plumb, the lesion had clinically disappeared. 1962; Kandil and Al-Kashlan, 1970). The disorder was originally described by Hoffmann (1923), who referred to it as 'simulation of primary syphilis by gonorrhoeal lymphangitis (gonorrhoeal pseudo- chancre)'. In a later paper Hoffmann (1938) called the condition a 'non-venereal plastic lymphangitis of the coronary sulcus of the penis with circumscribed edema'. The aetiology of the disorder is not known, copyright. but its non-venereal nature has been stressed in subsequent reports (Nickel and Plumb, 1962; Kandil and Al-Kashlan, 1970). It has been suggested that it may be related to mechanical trauma, virus infection, irritation by menstrual blood, or tuber- culosis. NSLP appears suddenly as a firm, cordlike, encircle the translucent lesion, which may almost http://sti.bmj.com/ penis in the coronal sulcus. The histological findings suggest that it results from fibrotic thickening of a large lymph vessel.
    [Show full text]
  • Stanford Emergency Department & Clinical
    STANFORD EMERGENCY DEPARTMENT & CLINICAL DECISION UNIT EMPIRIC ANTIBIOTIC GUIDELINES FOR ACUTE BACTERIAL SKIN AND SKIN-STRUCTURE INFECTIONS PURULENT CELLULITIS (cutaneous abscess, carbuncle, furuncle) Common pathogen: Staphylococcus aureus Duration of Therapy: 5-10 days Condition/Severity Admit/CDU/Discharge Cultures? Antibiotic Recommendation Mild < 5 cm Discharge No I&D Only ± TMP-SMX DS 1-2 PO BID Mild > 5 cm Discharge Yes – I&D plus Antibiotics: wound TMP-SMX DS 1-2 PO BID Typical abscess +/- cellulitis with no I&D systemic signs of infection Alternative: Doxycycline 100 mg PO BID Moderate Discharge Yes – TMP-SMX DS 1-2 PO BID wound only one Purulent infection with I&D Alternative: Doxycycline 100 mg PO BID systemic sign of infection: CDU if any factors below1,2: EMPIRIC ANTIBIOTICS: temp>38°C - • Concern for poor adherence to therapy TMP-SMX DS 1-2 PO BID HR >90 bpm - • Exacerbation of comorbidities RR>24 bpm Alternative: - • Significant clinical concern Yes – abnormal WBC >12K or <400 • Doxycycline 100 mg PO BID - Note: cutaneous inflammation and systemic wound cells/mcg/L features often worsen after initiating therapy I&D Lymphangitis DEFINITIVE ANTIBIOTICS: - and failure to improve at 24 hours NOT MRSA: TMP-SMX DS 1-2 PO BID considered clinical failure MSSA: dicloxacillin 500mg PO QID or cephalexin 500mg PO QID Severe EMPIRIC ANTIBIOTICS: Vancomycin Per Pharmacy • Hypotension Alternatives: Consult pharmacy for restricted antibiotics • 2 or more systemic signs of Admission Yes - infection blood DEFINITIVE ANTIBIOTICS: - temp>38°C MRSA: Vancomycin - HR >90 bpm MSSA: Cefazolin 2g IV Q8H - RR>24 bpm - abnormal WBC >12K or <400 cells/mcg/L - Lymphangitis • Immunocompromised** CELLULITIS (NON-PURULENT) Common pathogens: Streptococcus spp (usually S.
    [Show full text]
  • Communicable Disease Case Counts 2014-2018
    Report 4: Table of Diseases Comparing A Given Timeframe for Past 5 Years Case Types: Individual Cases Only Case Status: Confirmed, Probable Year: 2014-2018 Investigation Status: Completed Display Interval: By Year Jurisdictions: Mid-Michigan District Report Type: Counts Disease Group Disease 2014 2015 2016 2017 2018 Total AIDS/HIV AIDS, Aggregate 0 0 0 0 0 0 HIV/AIDS, Adult 3 2 0 0 0 5 HIV/AIDS, Pediatric 0 0 0 0 0 0 Subtotal 3 2 0 0 0 5 Foodborne Amebiasis 1 0 0 1 0 2 Botulism - Foodborne 0 0 0 0 0 0 Campylobacter 14 31 17 20 12 94 Cryptosporidiosis 7 6 13 15 7 48 Escherichia coli 0157:H7 (Pre-2011)* 0 0 0 0 0 0 Giardiasis 19 10 8 14 3 54 Listeriosis 0 0 0 0 0 0 Listeriosis (2014- 2017)* 1 0 0 0 0 1 Listeriosis (Pre-2014)* 0 0 0 0 0 0 Norovirus 4 1 13 7 5 30 Paratyphoid Fever 0 0 0 0 0 0 Salmonellosis 10 12 24 20 20 86 Shiga toxin, E. Coli, Non O157 (Pre- 2011)* 0 0 0 0 0 0 Shiga toxin, E. Coli, Unsp (Pre-2011)* 0 0 0 0 0 0 Shiga toxin-producing Escherichia coli -- (STEC) 4 1 4 0 3 12 Shigellosis 3 5 13 5 2 28 Typhoid Fever 0 0 0 0 0 0 Yersinia enteritis 0 1 1 0 0 2 Subtotal 63 67 93 82 52 357 Influenza Flu Like Disease* 0 0 0 0 0 0 Influenza 37 63 49 231 278 658 Influenza, 2009 Novel* 0 0 0 0 0 0 Influenza, Novel 0 0 0 0 0 0 Subtotal 37 63 49 231 278 658 Meningitis Meningitis - Aseptic 6 21 11 9 13 60 Meningitis - Bacterial Other 1 3 2 3 7 16 Meningococcal Disease 0 1 0 0 0 1 Streptococcus pneumoniae, Inv 8 20 25 20 24 97 Subtotal 15 45 38 32 44 174 01-17-2019 1 of 5 Disease Group Disease 2014 2015 2016 2017 2018 Total Other Acute Flaccid
    [Show full text]
  • Lymphographic Studies in Acute Lymphogranuloma Venereum Infection
    Brit. J7. vener. Dis. (1976) 52, 399 Br J Vener Dis: first published as 10.1136/sti.52.6.399 on 1 December 1976. Downloaded from Lymphographic studies in acute lymphogranuloma venereum infection A. 0. OSOBA AND C. A. BEETLESTONE From the Special Treatment Clinic and the Departments of Medical Microbology and Radiology, University of Ibadan, Nigeria Summary 1954) described a convenient method of cannulating Lymphography, a radiological method of demon- the lymph vessels and injecting water-soluble strating lymphatic channels and nodes, has been contrastmedium, the procedurehas become extensively used to investigate three cases of acute bubonic used. Lymphography has been used in a variety of lymphogranuloma venereum (LGV). There is conditions in which the pathological process origi- nates in or is associated with lymph nodes (Koehler, general agreement that LGV has a predilection for 1968a, b). In lymphomas, the lymphographic lymphatic channels and lymph nodes. However, appearance can be pathognomonic, hence much very little is known of the extent of lymph node excellent work has been done in this field (Abrams, involvement in the early bubonic stage and whether Takahashi, and Adams, 1968; Lee, 1968; Rosenberg, there is merely a lymphangitis or complete lymph- 1968). However, little work has been done on atic obstruction. inflammatory conditions such as tuberculosis, syphilis The present study was undertaken to determine and lymphogranuloma venereum (LGV), which copyright. the lymphographic appearance in acute bubonic produce lesions in lymph glands. Because lympho- LGV, the extent of lymphatic node involvement in graphy is the only direct method of visualizing the early LGV, and the usefulness of the procedure in lymphatics and lymph nodes, and since it can objectively evaluate the inaccessible pelvic and the management of LGV patients.
    [Show full text]
  • Monthly Reportable Diseases Summary
    Monthly Reportable Diseases Summary June 2021 The data in the Monthly Disease Reports are provisional, based on current reports in the Michigan Disease Surveillance System (MDSS) made by local public health departments. The MDSS is a dynamic, continually active system; counts of disease are constantly changing as cases are investigated, confirmed as cases, or ruled out as not meeting the case definition. Each Monthly Disease Report reflects this constant activity as the numbers may slightly fluctuate each month. Therefore, it should be kept in mind that numbers in the Monthly Disease Reports are NOT final and should be used only to generally monitor Ottawa County trends over time. Unknown, suspect, probable and confirmed cases of the reportable condition are included in the report. An updated report is published each month. Specific data requests and questions should be directed to the following: Compiled by Derick N. Chia, MPH Epidemiologist [email protected] We value your feedback. Please use this QR code or click on the link below to tell us what you think of this report: Link to Survey 12251 James Street Holland, MI 49424-9661 www.miottawa.org/healthdata June 2021 Reportable conditions that are italicized have an accompanying graph at the end of the monthly section. Cases Reported in Last 4 Months** Year Total Through June Year End Disease Group Reportable Condition Mar-21 Apr-21 May-21 Jun-21 2018 2019 2020 2021 2020 Foodborne Amebiasis - 1 - - - - - 1 - Botulism - Foodborne - - - - - - - - - Campylobacter 2 4 1 6 33 29 16 22
    [Show full text]
  • NYC Health Code and Rules – Article 11- Reportable Diseases And
    ARTICLE 11 REPORTABLE DISEASES AND CONDITIONS §11.01 Definitions. §11.03 Diseases and conditions of public health interest that are reportable. §11.04 Report of First-Episode Psychosis §11.05 Reports. §11.07 Immunization Registry. §11.09 Blood Lead Reporting and Children's Blood Lead Registry. §11.10 Neonatal herpes simplex. §11.11 Confidentiality of reports and records. §11.13 Duty of physician to advise case, suspect case, carrier, suspect carrier and contact. §11.15 Control measures; duty to exclude; exclusion orders. §11.17 Control measures; duty to isolate; and isolation, quarantine and examination orders. §11.19 Typhoid and paratyphoid fever; exclusion. §11.21 Tuberculosis; reporting, examination, treatment, exclusion, removal and detention. §11.23 Removal and detention of cases, contacts and carriers who are or may be a danger to public health; other orders. §11.25 Reports and control of animal diseases communicable to humans. §11.27 Control of animals affected with rabies. §11.29 Rabies: compulsory vaccination. §11.31 Acts likely to spread disease prohibited. §11.33 Congenital Syphilis. §11.01 Definitions. When used in this article: (a) "Carrier" means an individual who, without showing any evidence of clinical disease, harbors and is capable of transmitting an infectious agent and may be a potential source of infection to others. (b) "Case" means, depending on the context, (1) an individual who, based on clinical, laboratory and/or epidemiologic evidence or other recognized public health criteria, has a disease or condition of public health interest that is reportable to the Department pursuant to this article or any other applicable law or regulation, or (2) an instance of such a reportable disease or condition occurring in an individual.
    [Show full text]
  • KDHE's Notifiable Disease List
    REPORTABLE DISEASES IN KANSAS (K.S.A. 65-118, 65-128, 65-6001 - 65-6007, K.A.R. 28-1-2, 28-1-4, and 28-1-18. Changes effective as of 5/11/2018) For 4-hour reportable diseases report to the KDHE Epidemiology Hotline: 877-427-7317. For all other reportable diseases fax a Kansas Reportable Disease Form and any lab results to your local health department or to KDHE: 877-427-7318 within 24 hours or by the next business day. Acute flaccid myelitis Influenza, novel A virus infection Anthrax Legionellosis Anaplasmosis Listeriosis Arboviral disease, neuroinvasive and nonneuroinvasive Lyme disease (including chikungunya virus, dengue virus, La Malaria Crosse, West Nile virus, and Zika virus) Measles (rubeola) Babesiosis Meningococcal disease Blood lead levels (any results) Mumps Botulism Pertussis (whooping cough) Brucellosis Plague (Yersinia pestis) Campylobacteriosis Poliovirus Candida auris Psittacosis Carbapenem-resistant bacterial infection or Q Fever (Coxiella burnetii, acute and chronic) colonization Rabies, human Carbon monoxide poisoning Rabies, animal Chancroid Rubella Chickenpox (varicella) Salmonellosis, including typhoid fever Chlamydia trachomatis infection Severe Acute Respiratory Syndrome-associated Cholera coronavirus (SARS-CoV) Coccidioidomycosis Shiga toxin-producing Escherichia coli (STEC) Cryptosporidiosis Shigellosis Cyclosporiasis Smallpox Diphtheria Spotted fever rickettsiosis Ehrlichiosis Streptococcus pneumoniae, invasive disease Giardiasis Syphilis, all stages, including congenital syphilis Gonorrhea
    [Show full text]